ORIGINAL ARTICLES

Maternal insulin-like growth factor binding protein-1, body mass index, and fetal growth

Robert P Holmes, J M P Holly, Peter W Soothill

Abstract

Aim—To examine the hypothesis that the maternal insulin-like growth factor system may constrain fetal growth.

Methods—A prospective observational study of maternal serum insulin-like growth factor binding protein-1 (IGFBP-1) and fetal growth was undertaken in neonates with birthweights below the 5th centile. They had been classified either as having fetal growth restriction (FGR) due to placental dysfunction (increased umbilical artery Doppler pulsatility index (PI); n = 25) or as being small for gestational age (SGA; normal umbilical artery PI, growth velocity and amniotic fluid; n = 27). Eighty nine controls had normal birthweights (5th–95th centile), umbilical artery PI, growth velocity, and amniotic fluid. IGFBP-1 was measured by radioimmunoassay.

Results—Among the controls, there was no significant correlation between IGFBP-1 and birthweight after allowing for body mass index (BMI). Maternal BMI was high in FGR and after adjusting for this, IGFBP-1 was increased (109 ng/ml) compared with SGA babies (69 ng/ml) and controls (57 ng/ml) and correlated with the umbilical artery PI.

Conclusions—Maternal IGFBP-1 is probably not part of normal placental function. Its increase in FGR could be the cause or consequence of impaired placentation, but high IGFBP-1 concentrations might further reduce the availability of maternal IGF-I to the placenta. This could worsen placental function and so adversely affect fetal growth.

Arch Dis Child Fetal Neonatal Ed 2000;82:F113–F117

Keywords: insulin-like growth factor binding protein-1; growth restriction; umbilical artery; Doppler pulsatility index

Fetal growth is controlled by genetic, environmental, and nutritional factors. The non-genetic elements become increasingly important in the second half of pregnancy and contribute to the natural phenomenon of maternal constraint on the size of the baby, so overriding paternal genetic influences. Conversely, environmental factors might lead to fetal overgrowth, the most common example being maternal diabetes mellitus. Although the insulin-like growth factor (IGF) system mediates growth in response to nutritional signals in the fetus, the part played by the maternal IGF system is less well established.

IGF-I is an important growth factor and hormone which regulates protein turnover as well as having potent mitogenic and differentiating effects on most cell types. In mothers whose pregnancies incur fetal growth restriction (FGR) IGF-I concentrations are greatly reduced. In mice, increasing maternal IGF-I concentrations result in a heavier litter size and prevent the reduction in the average fetal weight which normally occurs with increasing litter number. Furthermore, in sheep, maternal IGF-I infusion results in increased fetal glucose concentrations and placental amino acid uptake, presumably via effects on placental function and transfer. These observations suggest that IGF-I might override the normal process of maternal constraint.

There are at least seven IGF binding proteins (IGFBP) that act not only as carrier proteins but also as regulators by controlling bioavailability of IGF-I to tissues. IGFBP-1 (synonymous with placental protein 12 and human pregnancy-associated endometrial α-1 globulin) has a molecular weight of 25 kiloDaltons and binds IGF-I to form a 34 kiloDalton complex. This complex can cross intact endothelium and so may be involved in delivery of IGF-I to the tissues. Although in theory this could enhance IGF-I availability, IGFBP-1 inhibits IGF-I action in most in vitro systems and in blood.

Several observations suggest that maternal IGFBP-1 is important in pregnancy. Concentrations rise rapidly in the first 12 weeks of pregnancy and remain high until delivery. The main source of this increased production is likely to be the decidualised endometrium. In the absence of pregnancy a single phosphorylated form of IGFBP-1 is secreted by the liver; in pregnancy less phosphorylated and non-phosphorylated forms with lower binding affinities are present, probably as a result of the action of a phosphatase secreted by decidua. Furthermore, increased IGFBP-1 concentrations have been reported in preterm delivery, pre-eclampsia, and gestational diabetes mellitus.
A significant correlation between maternal IGFBP-1 and birthweight has been reported by some groups but not all. Studies of unselected whole populations may detect correlations absent in studies of selected normal pregnancies because cases with pathology are included. Indeed, Baldwin et al observed low IGFBP-1 in diabetes, and Larsen et al showed high concentrations in FGR. Larsen et al found no correlation between IGFBP-1 and maternal weight but a negative association was reported by Baldwin et al and Hills et al. IGFBP-1 is closely involved in carbohydrate metabolism, being regulated by insulin, and as maternal size is also an important predictor of birthweight, the confounding effect of maternal size on the relation between IGFBP-1 and birthweight warranted further consideration.

To clarify these issues we undertook a longitudinal study of new groups of women with small and appropriately grown fetuses from 24 weeks to term. No data from the previous publication were included in this study. These pregnancies were followed prospectively until delivery with comprehensive assessment using ultrasound biometry and umbilical artery Doppler velocimetry. The pregnancies with small for gestational age (SGA) fetuses were further classified into two groups: those with normal placental function, growing to their genetic potential (SGA), and those with fetal growth restriction (FGR) due to placental dysfunction.

Methods

This was a prospective, observational study of 75 women, each of whom had a singleton fetus with an ultrasonographically defined abdominal circumference (AC) measurement smaller than −2 standard deviations (SD) for gestational age in the second half of pregnancy (Harris Birthright Trust Database, Viewpoint, Bildverarbeitung, Gmb, Gilching, Germany). Fetal anatomy was inspected to exclude structural anomalies and markers of karyotypic abnormality or infection, and invasive testing was performed subsequently, as medically indicated. Placental function was assessed by umbilical artery Doppler velocimetry studies and measurement of the amniotic fluid index (AFI). At each visit, 2 ml of maternal venous blood were drawn into a fluoride tube for plasma random glucose measurement and 16 ml into two tubes without heparin. This was allowed to clot, centrifuged at 4000 rpm for five minutes, and the serum stored at −24°C. IGFBP-1 concentrations undergo marked diurnal variation but are relatively stable between 10:00 and 16:00 hours in late pregnancy and so non-fasting samples were taken within these hours.

Classification of cases and controls was made after delivery. Criteria for exclusion of potential cases were a birthweight greater than the 5th centile for gestational age (−1.645 SD) (n = 18) or evidence of structural (n = 0), chromosomal (n = 2), or infectious congenital anomalies (n = 1) at birth. Remaining cases were then separated on the basis of the last umbilical artery pulsatility index (PI) before delivery into two subgroups: FGR (due to placental dysfunction) and SGA (normal small).

The umbilical artery PI was expressed as multiples of SD of the normal mean for gestational age because it changes with gestational age, and a measurement exceeding +2 SD defined FGR. Doppler was used as the sole criterion for classifying FGR because it is the best clinical test of placental function and predicts outcome better than amniotic fluid assessment or cardiotocography. AFI measurement is more subjective and harder to reproduce than Doppler so an AFI less than the 5th centile was not used to define FGR in pregnancies with a normal umbilical artery PI. Nor were these pregnancies included in the SGA group because a severe reduction in amniotic fluid volume in the absence of fetal renal abnormality or ruptured membranes can be an indicator of early placental dysfunction. All SGA cases had an umbilical artery PI between −2 and +2 SD of the normal mean for gestational age and an AFI >5 cm. Fetuses defined as SGA by these criteria have a normal pregnancy outcome. The criteria for FGR and SGA were defined before the study with the aim of minimising mixing of the groups and so the final study groups comprised 25 FGR cases and 27 SGA cases.

Criteria for exclusion of potential controls were a birthweight less than the 5th centile for gestational age (−1.645 SD) (n = 7) or greater than the 95th centile (+1.645 SD) (n = 3), the development of gestational hypertension (n = 3) or diabetes (n = 1), a reduced AFI at term (n = 2), a reduced growth velocity at term (n = 2), or a birthweight less than the 5th centile for gestational age (−1.645 SD) (n = 3), the development of gestational hypertension (n = 3) or diabetes (n = 1), a reduced AFI at term (n = 2), a reduced growth velocity at term (n = 2), or a birthweight less than the 5th centile for gestational age (−1.645 SD) (n = 3), the development of gestational hypertension (n = 3) or diabetes (n = 1), a reduced AFI at term (n = 2), a reduced growth velocity at term (n = 2). No control developed an abnormal umbilical artery PI. The final number of controls for analysis was 89. The case and control criteria were agreed before the study, with the aim of preventing misclassification and all exclusions were made before any serum samples were analysed.
Maternal IGFBP-1, body mass index, and fetal growth

The last maternal serum sample obtained before labour from the 52 FGR and SGA cases was analysed. A cross sectional normal range with an even gestational age spread of results from 24 to 42 weeks was constructed by selecting a single sample from each of the 89 controls (before any laboratory work) stratifying by gestational age.

IGFBP-1 was assayed using a specific radioimmunoassay. Recombinant human IGFBP-1 was kindly supplied by Synergen (Boulder, Colorado, USA) and used for both standards and 125I tracer. A polyclonal antiserum raised in sheep against purified human IGFBP-1 (S515) was used. Phosphate buffered saline assay (0.25 M with 28.4 g/l disodium hydrogen orthophosphate, 6.81 g/l potassium dihydrogen orthophosphate, 48.83 g/l sodium chloride, 0.35 g/l sodium azide adjusted to pH 7.5 and diluted five times in water and 10% horse serum) was used to dilute the IGFBP-1 antibody which had a final dilution in the assay of 1 in 700 000. The standard curve had a range of 1–200 ng/ml. The intra-assay coefficients of variation using the same assay, but at a wider range (1–400 ng/ml), were 10.3% and 9.1% at 9 ng/ml and 353 ng/ml, respectively, and the interassay coefficients of variation were 10.6% and 7.0% at 106 ng/ml and 235 ng/ml, respectively. The limit of detection of the assay was 6 ng/ml.

Normality of distribution was assessed by the Shapiro–Wilk test after log10 transformation if required. IGFBP-1 was only normally distributed after this transformation so all subsequent analysis was on log10 IGFBP-1. Maternal characteristics and serum IGFBP-1 were compared between the groups using one way analysis of variance following Dunnett’s test. Both birthweight and umbilical artery PI change with gestational age in control pregnancies and so results were expressed as multiples of SD of the normal mean for gestational age (z score). In control pregnancies, birthweight SD, umbilical artery PI SD, maternal BMI, weight and height were tested for correlation with log10 transformation of IGFBP-1 using linear regression analysis.

Multiple regression analysis was used to adjust for the confounding effect of BMI on the relation between log IGFBP-1 and birthweight SD and on the differences in log IGFBP-1 concentrations in the FGR, SGA, and control groups using two dummy variables.

Results

Maternal characteristics in the control, SGA, and FGR groups are shown in table 1. The mean age of SGA mothers (24.8 years) was significantly lower than that of control mothers (29.3 years, p < 0.05), but the age of FGR mothers was similar to that of the controls (30.2 years). The mean maternal BMI in FGR (26.9 kg/m2) was significantly higher than that of controls (22.8 kg/m2, p < 0.05) whereas the mean maternal BMI in SGA was not (22.5 kg/m2). The mean weight of FGR mothers (67.9 kg) was also significantly higher than that of the controls (60.6 kg, p < 0.05) while the mean weight of SGA mothers was similar (59.3 kg). Height and random plasma glucose were similar in all groups.

The IGFBP-1 concentrations in control pregnancies by gestational age are shown in figure 1. After log10 transformation, these data were normally distributed and there was no change in maternal serum log. IGFBP-1 with advancing gestational age (r = 0.15, n = 89). The mean control IGFBP-1 concentration was 57 ng/ml. There was a significant negative correlation between control log. IGFBP-1 and birthweight SD (r = −0.22, n = 89, p < 0.04) and maternal BMI (r = −0.30, n = 89, p < 0.005), but not between control log. IGFBP-1 and maternal weight or height. Therefore, it was essential to remove the effect of BMI on IGFBP-1 in all subsequent analyses.

After adjusting for the effect of maternal BMI, using multiple regression analysis, there was no independent significant correlation between control log. IGFBP-1 and birthweight SD. The correlation between control log. IGFBP-1 and maternal BMI remained significant after removing the effect of birthweight SD (p = 0.01).

After adjusting for maternal BMI, the mean IGFBP-1 in the FGR group (109 ng/ml) was increased compared with that in the control group (57 ng/ml, p = 0.003) but the mean concentration in SGA cases (69 ng/ml) was similar to that of controls. In the FGR group, but not the SGA group, there was a significant negative correlation between log. IGFBP-1 and birthweight SD score (r = −0.47, n = 27, p < 0.04) which was no longer significant after allowing for the effect of BMI. Log. IGFBP-1 correlated with the severity of placental dysfunction as indicated by umbilical artery PI (r = 0.26, n = 141, p = 0.002).

<table>
<thead>
<tr>
<th>Table 1 Maternal characteristics in pregnancies with normally grown, SGA, and FGR fetuses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Controls (n = 89)</strong></td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Body mass index</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Random plasma glucose (mmol/l)</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
</tbody>
</table>

SGA, small for gestational age; FGR, fetal growth restriction.
*Significantly different from controls by one way analysis of variance followed by Dunnett’s test (p < 0.05)
Discussion
Within normal control pregnancies we found a weak negative correlation between IGFBP-1 and birthweight similar to that reported by Hills et al., but we have shown that this was explained by the confounding correlation of IGFBP-1 with maternal BMI. This indicates that the link between IGFBP-1 and birthweight in normal pregnancies relates to nutrition, carbohydrate metabolism, and adiposity especially as maternal height (a reflection of genetic growth potential) did not correlate with IGFBP-1 in our study. IGFBP-1 is closely involved in acute glucose regulation11 as both are controlled by insulin.22 Maternal IGFBP-1 is low in gestational diabetes,6 and insulin sensitivity in diabetics is an important independent predictor of birthweight.23 Women with the polycystic ovarian syndrome have low IGFBP-1 concentrations which are related to insulin sensitivity even after controlling for increased BMI.24 These observations suggest that the explanation for our finding of an association between IGFBP-1 and birthweight confounded by BMI might be due to insulin sensitivity.

The absence of a relation between birthweight and maternal IGFBP-1 in the control pregnancies, after adjusting for BMI, is further emphasised by the finding that IGFBP-1 was unchanged in the mothers of SGA cases. This was despite our rigorous definition of SGA (below the 5th centile or −1.645 SD of the control mean for gestational age) which resulted in a mean birthweight SD for the group of −2.01 SD, much smaller than would have been attained by using the conventional SGA definition of birthweight below the 10th centile (−1.28 SD). However, the maternal height, weight, BMI and random blood sugar centile (−1.28 SD). However, the maternal height, weight, BMI and random blood sugar were similar to those of controls and there was no increase in adverse perinatal outcome, so we consider these pregnancies to be normal, the fetuses having grown to their genetic potential. We would anticipate normal nutrition and glucose metabolism in these women.

Our findings of increased maternal IGFBP-1 concentrations, after adjusting for BMI in pregnancies complicated by FGR but not SGA, are consistent with previous observations.11 In the FGR but not the SGA group there was a significant correlation between IGFBP-1 and birthweight SD. IGFBP-1 inhibits the actions of IGF-I in most systems studied and so the consequence of high IGFBP-1 in FGR may be to further reduce availability of the already low maternal IGF-I concentrations in these cases.20 In animal studies placental nutrient transfer was increased when maternal IGF-I concentrations were raised,21 so very low unbound IGF-I in FGR could be detrimental to the already compromised placental function. High maternal IGFBP-1 in FGR might also protect the fetus because glucose transfer to an already hypoxic fetus may cause lactic acid accumulation and acidosis.22 However, the high IGFBP-1 is unlikely to be an adaptive protective mechanism because a correlation between eventual birthweight and IGFBP-1 has been reported as early as 11 weeks of gestation,3 a stage in pregnancy when the metabolic demands of the fetus are still low.

High maternal IGFBP-1 in FGR is unlikely to be related to maternal carbohydrate metabolism because these women were not malnourished and there was no evidence of altered glucose tolerance. Indeed, their median BMI was significantly higher than that of the controls so low IGFBP-1 concentrations would have been anticipated. The high BMI we observed in FGR supports the hypothesis that small maternal stature is not a risk factor for FGR and that most small fetuses of low BMI women are normally grown to their genetic potential and are not a consequence of placental dysfunction.

Our study showed a correlation between IGFBP-1 and worsening placental function, assessed by abnormal blood velocity waveforms in the umbilical artery. It is well established that these Doppler changes indicate characteristic pathological changes in the placenta.25 It therefore seems likely that high maternal IGFBP-1 concentrations in FGR may be a consequence of abnormal placental development. This is supported by the observation that IGFBP-1 is high in pre-eclamptics, especially if associated with proteinuria. In such cases abnormalities of the uteroplacental circulatory may be already present in the early second trimester. It has been suggested that hypoxia itself might increase gene expression for IGFBP-1,26 so changes within the decidua as a result of hypoxia due to poor development of maternal spiral artery vasculature could induce IGFBP-1. This may prevent trophoblast invasion continuing beyond that which could be supported by the decidua. For these reasons the high maternal IGFBP-1 concentrations which we observed in FGR in the second half of pregnancy could be the consequence of persisting placental hypoxia and would explain the correlation between IGFBP-1 and umbilical artery Doppler. The wide variation in concentrations found in our FGR cases suggest that IGFBP-1 is unlikely to be a clinically useful biochemical marker of placental dysfunction. Whether standardised fasting
Maternal IGFBP-1, body mass index, and fetal growth

concentrations, or expression of the data as a ratio to IGF-I or IGFBP-1 response to a glucose challenge, would have a better specificity and sensitivity remains to be explored.

The high concentrations could even be causal because it has been suggested that IGFBP-1 synthesised in the decidua from early in pregnancy may inhibit trophoblast invasion. The observation that IGFBP-1 inhibits the mitogenic effects of IGFs on endometrial stromal cells supports an inhibitory role for IGFBP-1 in early placental development. IGFBP-1 mRNA is expressed in the glands and stromal cells of the decidua rather than the placenta, suggesting a role in communication at the feto-maternal interface, but a direct inhibitory growth effect on the placenta itself is possible due to the close proximity of the decidua to the trophoblast.

Our understanding of the maternal IGF system is still far from complete but our data support the hypothesis that the system is related to placental dysfunction and maternal metabolic adaptations to pregnancy.

We thank Dr Linda Hunt, Department of Child Health at the Royal Hospital for Sick Children, Bristol for her statistical advice.

Maternal insulin-like growth factor binding protein-1, body mass index, and fetal growth

Robert P Holmes, J M P Holly and Peter W Soothill

Arch Dis Child Fetal Neonatal Ed 2000 82: F113-F117
doi: 10.1136/fn.82.2.F113

Updated information and services can be found at:
http://fn.bmj.com/content/82/2/F113

These include:

References
This article cites 28 articles, 5 of which you can access for free at:
http://fn.bmj.com/content/82/2/F113#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: CNS (not psychiatric) (191)
- Drugs: endocrine system (81)
- Pregnancy (1521)
- Reproductive medicine (1433)
- Immunology (including allergy) (393)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/